Tag : Presented

Latest News

Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting

Newsemia
PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY–Studies Evaluating Liso-Cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology Source link...
Latest News

Positive Data from First Clinical Study of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor Designed for First Point-of-Contact STEMI Therapy, Presented at AHA 2019 Late-Breaking Science Session

Newsemia
SAN DIEGO–(BUSINESS WIRE)–Data from a completed clinical study show RUC-4 provided a potent, rapid, and sustained platelet inhibition effect in stable CAD patients w/aspirin. Source...
Gastroenterology

New Clinical Advances in Gastroenterology Presented at the American College of Gastroenterology's 84th Annual Scientific Meeting

Newsemia
The American College of Gastroenterology Annual Scientific Meeting features innovative clinical gastroenterology research with implications for patients with digestive and liver diseases. ACG’s Public Relations...
Latest News

New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1

Newsemia
CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced results of a Phase 1 clinical proof of concept study of the novel...
Latest News

Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting

Newsemia
HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting Source link...
Latest News

Promising Clinical Data from Pilot Study of Gelesis’ Novel Hydrogel GS500 Prototype for the Potential Treatment of Chronic Constipation Presented at Digestive Disease Week by Researchers from Massachusetts General Hospital and Brigham and Women’s Hospital

Newsemia
BOSTON–(BUSINESS WIRE)–Gelesis announced the presentation of data from a clinical study of GS500 for potential treatment of chronic constipation at Digestive Disease Week. Source link...
Latest News

Results of Phase 3 Trial Evaluating Merck’s ZERBAXA® (ceftolozane and tazobactam) versus Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia (VNP) to be Presented at ECCMID 2019

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank"gt;#MRKlt;/agt;–Phase 3 Trial Results Evaluating Merck’s ZERBAXA® vs Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia...
Latest News

Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting

Newsemia
HOUSTON–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;–Gamida Cell announced that translational data from the completed Phase 1/2 clinical study of NiCord® were reported at the 2019 TCT Annual...
AI/ML

Artificial intelligence and machine learning for human reproduction and embryology presented at ASRM and ESHRE 2018.

Newsemia
Related Articles Artificial intelligence and machine learning for human reproduction and embryology presented at ASRM and ESHRE 2018. J Assist Reprod Genet. 2019 Jan 28;:...
Latest News

Generon Presented Positive Phase III Results From a Double-Blind, Placebo Controlled-Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

Newsemia
SHANGHAI–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/BreastCancerSymposium?src=hash" target="_blank"gt;#BreastCancerSymposiumlt;/agt;–Generon announced at the SABCS positive results from a placebo-controlled trial with F-627, designed using Generon’s DikineTM technology platform. Source link...
Latest News

Generon Presented Pre-Clinical Immunotherapy Results With CD3-Activating Bi-Specific Antibody Targeting CD19 on B Cells in Mono- and Bi-Valent Format

Newsemia
SHANGHAI–(BUSINESS WIRE)–#AmericanSocietyOfHematology–Generon presented pre-clinical immunotherapy results with CD3-activating bi-specific antibody targeting CD19 on B cells Source link...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy